Dr. Andrew Adams serves as the Group VP Molecule Discovery & Director of the Lilly Institute for Genetic Medicine. Andrew is responsible for leading the discovery of new therapies across Lilly, including small molecule, antibody, peptides and genetic medicines. Andrew also serves as head of research in our core strategic areas of pain and neurodegeneration. 

In his work leading the institute for genetic medicine, Andrew is responsible for developing our growing portfolio of genetic medicines at Lilly, spanning RNA, gene therapy and gene editing. 

Andrew holds a degree in biology and a doctorate in zoology from the University of Aberdeen, Scotland. Prior to joining Lilly in 2011, Andrew was a postdoctoral fellow at Harvard Medical School. During his time at Lilly, he has served in a number of roles in discovery, external innovation and as a leader of Lilly’s early discovery teams, spanning diabetes & complications, neuroscience, genetic medicine and most recently molecule discovery broadly.